Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — 9M 2012 Earnings Presentation
15 slides from Novo Nordisk A/s Class B's earnings presentation, Oct 31, 2012
Slide 1: Investor conference call: First nine months of 2012
Investor conference call First nine months of 2012
Slide 2: Agenda
Investor presentation First nine months of 2012 Slide no 2 Agenda Introduction by Lars Rebien Sørensen, CEO Sales update by Lars Rebien Sørensen, CEO R&D update by Mads Krogsgaard Thomsen, CSO Financials and outlook by Jesper Brandgaard, CFO Questions & answers session
Slide 3: Forward-looking statements
Investor presentation First nine months of 2012 Slide no 3 Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document as well as the company’s Annual Report 2011 and Form 20-F, both filed with the SEC in Febru
Slide 4: Highlights – first nine months of 2012
Investor presentation First nine months of 2012 Slide no 4 Highlights – first nine months of 2012 Sales development • Sales increased by 11% in local currencies and 18% in Danish kroner: • North America and International Operations increased by 19% and 16% in local currencies, respectively • Victoza
Slide 5: North America is the main contributor to growth
Investor presentation First nine months of 2012 Slide no 5 North America is the main contributor to growth – first nine months of 2012 Sales as reported Growth analysis Region China Local currencies Growth Share of +30% growth Japan & Korea North America 19% 64% +11% 9% Europe 2% 4% 9% International
Slide 6: Growth is driven by Modern insulins and Victoza
Investor presentation First nine months of 2012 Slide no 6 Growth is driven by Modern insulins and Victoza® – first nine months of 2012 Sales as reported Growth analysis Local currencies Growth Share of Norditropin® Other +3% growth +14% 3% Modern insulins 14% 54% NovoSeven® 8% Human insulins (2%) (
Slide 7: Growth in insulin is supported by strong underlying growth in modern insulin
Investor presentation First nine months of 2012 Slide no 7 Growth in insulin is supported by strong underlying growth in modern insulin and a stable market share Global insulin market Global modern insulin volume market shares tMU Device penetration Penetration Novo Nordisk Sanofi Eli Lilly Modern I
Slide 8: Strong underlying growth of Victoza supported by all regions
Investor presentation First nine months of 2012 Slide no 8 Strong underlying growth of Victoza® supported by all regions Victoza® sales split per region Reported Victoza® sales – first nine months of 2012 DKK North America Europe Region China billion Int. Operations Japan & Korea 5%1% 6% 25% 63% Q4
Slide 9: Regulatory update for Tresiba and Ryzodeg
Investor presentation First nine months of 2012 Slide no 9 Regulatory update for Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart) • FDA disclosed that the advisory committee meeting on 8 November 2012 will focus on the benefits USA of a lower risk of hypoglycaemia and the c
Slide 10: Other key events within Research and Development
Investor presentation First nine months of 2012 Slide no 10 Other key events within Research and Development Diabetes care • In a 26 week randomized extension trial in type 2 patients, once-daily Victoza® successfully improved HbA1c , and reduced body weight with a low risk of hypoglyceamia when add
Slide 11: Financial results – first nine months of 2012
Investor presentation First nine months of 2012 Slide no 11 Financial results – first nine months of 2012 DKK million First nine months 2012 First nine months 2011 Change Sales 57,064 48,226 18% Gross profit 46,752 38,759 21% Gross margin 81.9% 80.4% Sales and distribution costs 15,352 13,617 13% Pe
Slide 12: US dollar and Japanese Yen remain well above 2011 average
Investor presentation First nine months of 2012 Slide no 12 US dollar and Japanese Yen remain well above 2011 average 650 Spot rates Quarterly average Annual average Currency 2011 2012 Current assumptions1 average average rate2 600 USD/DKK USD 536 580 578 550 JPY 6.73 7.32 7.23 CNY 83 92 92 500 GBP
Slide 13: Financial outlook 2012
Investor presentation First nine months of 2012 Slide no 13 Financial outlook 2012 Expectations Previous expectations 31 October 2012 9 August 2012 Sales growth - local currencies 10-12% 9-12% Sales growth - reported Around 6 percentage points higher Around 7 percentage points higher Operating profi
Slide 14: Closing remarks
Investor presentation First nine months of 2012 Slide no 14 Closing remarks Solid market performance Promising pipeline • +10% annual diabetes care market growth • The only company with two new generation driven by diabetes prevalence1 insulins approaching the market • 25% market share in diabetes c
Slide 15: Investor information
Investor presentation First nine months of 2012 Slide no 15 Investor information Share information Investor Relations contacts Novo Nordisk’s B shares are listed on the stock exchange in Novo Nordisk A/S Copenhagen under the symbol ‘NOVO B’. Its ADRs are listed on Investor Relations the New York Sto